心力衰竭中缺铁的管理:基于证据的铁补充的实际考虑和实施
Kazuhiko Kido1, Craig J Beavers2, Kenneth Dulnuan3
1West Virginia University School of Pharmacy, Morgantown, West Virginia, USA.
JACC. Heart failure
|July 13, 2024
概括
缺铁 (ID) 影响了许多心力衰竭 (HF) 患者. 本综述探讨了静脉注射铁疗法的障碍,旨在改善ID的HF患者的治疗实施和治疗结果.
科学领域:
- 心脏病学 心脏病学
- 血液学 血液学 血液学
- 内部医学 内部医学
背景情况:
- 缺铁 (ID) 在心力衰竭 (HF) 患者中非常普遍,在后急性设置中达到80%.
- 目前的指导方针推静脉注射 (IV) 铁用于ID和减少喷射分数的HF患者,理由是改善了生活质量,运动能力和减少住院治疗.
研究的目的:
- 讨论在HF患者中治疗ID的实际考虑.
- 探索实施基于证据的IV铁疗法的策略,解决健康差异.
- 审查包括/排除标准,临床争议,以及在治疗HF的ID治疗中的证据差距.
主要方法:
- 这是一个复习文章.
- 它综合了当前关于高铁患者IV补充铁的证据和指导方针.
- 它确定了实施的障碍,并提出了解决方案.
主要成果:
- 在常规的IV铁实施中存在重大障碍,包括临床医生的知识差距和资源限制.
- 有效实施需要通过工具包和标准化协议来解决这些障碍.
- 证据缺口和临床争议需要进一步调查.
结论:
- 优化IV铁疗法对于ID的HF患者来说对于改善患者的治疗结果至关重要.
- 解决实际障碍和标准化治疗方案对于广泛,公平的实施至关重要.
- 需要进一步的研究来解决现有的证据缺口和临床争议.
更多相关视频
14:35Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
Published on: April 17, 2021
8.5K
05:23Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload
Published on: March 14, 2017
19.5K
相关概念视频
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
419
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
419
Pathophysiology of Heart Failure
1.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K
Heart Failure Drugs: β-Blockers
336
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
336
Heart Failure Drugs: Inotropic Agents
564
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
564
Heart Failure Drugs: Diuretics
362
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
362
